Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2014 | Research article

Serum TGF-β1 and SMAD3 levels are closely associated with coronary artery disease

Authors: Can Chen, Wei Lei, Wenjiang Chen, Jianfeng Zhong, Xiaoxin Gao, Bo Li, Huailong Wang, Congxin Huang

Published in: BMC Cardiovascular Disorders | Issue 1/2014

Abstract

Background

Coronary artery disease (CAD) is one of the most common diseases leading to mortality and morbidity worldwide. There is considerable debate on whether serum transforming growth factor β1 (TGF-β1) levels are associated with long-term major adverse cardiovascular events in patients with CAD, and to date, no study has specifically addressed levels in patients with different degrees of CAD severity.

Methods

Serum TGF-β1 and mothers against decapentaplegic homolog 3 (SMAD3) concentrations were evaluated in 279 patients with CAD and 268 controls without CAD. The clinical and biochemical characteristics of all subjects were also determined and analyzed.

Results

TGF-β1 and SMAD3 concentrations in CAD patients were significantly higher than those in the controls. The serum TGF-β1 level in acute myocardial infarction (AMI) was significantly higher than that in both stable angina pectoris (SAP) and unstable angina pectoris (UAP) (p < 0.05), while there was no marked difference between levels in SAP and UAP (p > 0.05). SMAD3 levels showed no obvious difference among AMI, SAP, and UAP. TGF-β1 and SMAD3 are potential biomarkers for CAD, and may be more accurate than Lpa, ApoA1, uric acid, BUN, or triglycerides (TG).

Conclusions

Serum TGF-β1 and SMAD3 levels are closely associated with CAD, and may become useful biomarkers for diagnosis and risk stratification.

Available only for authorised users

Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, et al: American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009, 119: 480-486.CrossRefPubMed

Minino AM: Death in the United States, 2009. NCHS Data Brief. 2011, 64: 1-8.PubMed

World Health Organization Cardiovascular Diseases (CVDs): Who Fact Sheet. 2011

Kathiresan S, Srivastava D: Genetics of human cardiovascular disease. Cell. 2012, 148: 1242-1257. 10.1016/j.cell.2012.03.001.CrossRefPubMedPubMedCentral

Stylianou IM, Bauer RC, Reilly MP, Rader DJ: Genetic basis of atherosclerosis: insights from mice and humans. Circ Res. 2012, 110: 337-355. 10.1161/CIRCRESAHA.110.230854.CrossRefPubMedPubMedCentral

Tayebi N, Ke T, Foo JN, Friedlander Y, Liu J, Heng CK: Association of single nucleotide polymorphism rs6903956 on chromosome 6p24.1 with coronary artery disease and lipid levels in different ethnic groups of the Singaporean population. Clin Biochem. 2013, 46: 755-759. 10.1016/j.clinbiochem.2013.01.004.CrossRefPubMed

Sugamura K, Keaney JF: Reactive oxygen species in cardiovascular disease. Free Radic Biol Med. 2011, 51: 978-992. 10.1016/j.freeradbiomed.2011.05.004.CrossRefPubMedPubMedCentral

Tousoulis D, Kampoli AM, Papageorgiou N, Androulakis E, Antoniades C, Toutouzas K, Stefanadis C: Pathophysiology of atherosclerosis: the role of inflammation. Curr Pharm Des. 2011, 17: 4089-4110. 10.2174/138161211798764843.CrossRefPubMed

Schaan BD, Quadros AS, Sarmento-Leite R, De Lucca G, Jr BA, Bertoluci M: 'Correction:' Serum transforming growth factor beta-1 (TGF-beta-1) levels in diabetic patients are not associated with pre-existent coronary artery disease. Cardiovasc Diabetol. 2007, 6: 19-10.1186/1475-2840-6-19.CrossRefPubMedPubMedCentral

10.

Grainger DJ: TGF-beta and atherosclerosis in man. Cardiovasc Res. 2007, 74: 213-222. 10.1016/j.cardiores.2007.02.022.CrossRefPubMed

11.

Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL: Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem. 2000, 275: 36803-36810. 10.1074/jbc.M005912200.CrossRefPubMed

12.

Caraci F, Battaglia G, Busceti C, Biagioni F, Mastroiacovo F, Bosco P, Drago F, Nicoletti F, Sortino MA, Copani A: TGF-beta 1 protects against Abeta-neurotoxicity via the phosphatidylinositol-3-kinase pathway. Neurobiol Dis. 2008, 30: 234-242. 10.1016/j.nbd.2008.01.007.CrossRefPubMed

13.

Edlin RS, Tsai S, Yamanouchi D, Wang C, Liu B, Kent KC: Characterization of primary and restenotic atherosclerotic plaque from the superficial femoral artery: potential role of Smad3 in regulation of SMC proliferation. J Vasc Surg. 2009, 49: 1289-1295. 10.1016/j.jvs.2008.11.096.CrossRefPubMedPubMedCentral

14.

Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K: Two major Smad pathways in TGF- superfamily signalling. Genes Cell. 2002, 7: 1191-1204. 10.1046/j.1365-2443.2002.00599.x.CrossRef

15.

Xu F, Lin SH, Yang YZ, Guo R, Cao J, Liu Q: The effect of curcumin on sepsis-induced acute lung injury in a rat model through the inhibition of the TGF-β1/SMAD3 pathway. Int Immunopharmacol. 2013, 16: 1-6. 10.1016/j.intimp.2013.03.014.CrossRefPubMed

16.

Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003, 425: 577-584. 10.1038/nature02006.CrossRefPubMed

17.

Zhu Y, Culmsee C, Klumpp S, Krieglstein J: Neuroprotection by transforming growth factor-beta1 involves activation of nuclear factor-kappaB through phosphatidylinositol-3-OH kinase/Akt and mitogen-activated protein kinase-extracellular-signal regulated kinase1,2 signaling pathways. Neuroscience. 2004, 123: 806-897.CrossRef

18.

Goel SA, Guo LW, Shi XD, Kundi R, Sovinski G, Seedial S, Liu B, Kent KC: Preferential secretion of collagen type 3 versus type 1 from adventitial fibroblasts stimulated by TGF-β/Smad3-treated medial smooth muscle cells. Cell Signal. 2013, 25: 9559-9560.CrossRef

19.

Dobaczewski M, Chen W, Frangogiannis NG: Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol. 2011, 51: 600-606. 10.1016/j.yjmcc.2010.10.033.CrossRefPubMed

20.

Bujak M, Frangogiannis NG: The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007, 74: 184-195. 10.1016/j.cardiores.2006.10.002.CrossRefPubMed

21.

Liu B, Zhang YM: Study on risk factors of premature coronary artery disease. Chin J Cardiovasc Res. 2009, 7: 629-632.

22.

Lin WT, Wu XN, Zhu PP, Zhang ZF, Chen J: Studies on anti-tumor activities of enteromorpha chlorella growth factor in experimental liver cancer and its mechanism. J Fujian Med Univ. 2009, 43: 227-230.

23.

Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A: The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med. 1995, 1: 74-79. 10.1038/nm0195-74.CrossRefPubMed

24.

Crook R, Leatham EW, Salomone OA, Hossein-Nia M, Grainger DJ, Kaski JC: Plasma levels of active transforming growth factor-beta are reduced in patients with three vessel coronary artery disease. Heart. 1996, 75: 79-

25.

Tashiro H, Shimokawa H, Yamamoto K, Momohara M, Tada H, Takeshita A: Altered plasma levels of cytokines in patients with ischemic heart disease. Coron Artery Dis. 1997, 8: 143-147. 10.1097/00019501-199703000-00004.CrossRefPubMed

26.

Li CG, Bethell H, Wilson PB, Bhatnagar D, Walker MG, Kumar S: The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease. Atherosclerosis. 2000, 152: 249-256. 10.1016/S0021-9150(99)00476-1.CrossRefPubMed

27.

Batuman O, Go D, Clark LT, Smith EL, Clements P, Feit A, Lederer D: Relationship between cytokine levels and coronary artery disease in women. Heart Dis. 2001, 3: 80-84.CrossRefPubMed

28.

Border WA, Ruoslahti E: Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest. 1992, 90: 1-7. 10.1172/JCI115821.CrossRefPubMedPubMedCentral

29.

Tashiro H, Shimokawa H, Sadamatu K, Yamamoto K: Prognostic significance of plasma concentrations of transforming growth factor-beta in patients with coronary artery disease. Coron Artery Dis. 2002, 13: 139-143. 10.1097/00019501-200205000-00001.CrossRefPubMed

30.

Stefoni S, Cianciolo G, Donati G, Dormi A, Silvestri MG, Coli L, De Pascalis A, Iannelli S: Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int. 2002, 61: 324-335. 10.1046/j.1523-1755.2002.00119.x.CrossRefPubMed

31.

Os I, Djurovic S, Seljeflot I, Berg K: Transforming growth factor (TGF)-beta1 inversely related to vascular cell adhesion molecule-1 in postmenopausal women with coronary artery disease. A possible mechanism for the putative cardioprotective role of TGF-beta1?. J Intern Med. 2002, 251: 223-227. 10.1046/j.1365-2796.2002.00950.x.CrossRefPubMed

32.

Wen HH, Bai P, Niu LJ, Li YD: The influence of serum uric acid on acute myocardial infarction and its predicative value. Acta Acad Med Nei Mongol. 2006, 28: 27-31.

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2261/14/18/prepub

Title: Serum TGF-β1 and SMAD3 levels are closely associated with coronary artery disease
Authors: Can Chen
Wei Lei
Wenjiang Chen
Jianfeng Zhong
Xiaoxin Gao
Bo Li
Huailong Wang
Congxin Huang
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: BMC Cardiovascular Disorders / Issue 1/2014
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/1471-2261-14-18

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Serum TGF-β1 and SMAD3 levels are closely associated with coronary artery disease

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Repeated epinephrine doses during prolonged cardiopulmonary resuscitation have limited effects on myocardial blood flow: a randomized porcine study

Prevalence and risk factors of abnormal left ventricular geometrical patterns in untreated hypertensive patients

Validation of continuous clinical indices of cardiometabolic risk in a cohort of Australian adults

Utility of NT-proBNP as a rule-out test for left ventricular dysfunction in very old people with limiting dyspnoea: the Newcastle 85+ Study

Association and predictive value analysis for metabolic syndrome on systolic and diastolic heart failure in high-risk patients

Metformin use in patients with type 2 diabetes mellitus is associated with reduced risk of deep vein thrombosis: a non-randomized, pair-matched cohort study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page